Document is current
Any future updates will be listed below
-
Authors
Figueras-Roca, Marc
Laraña, Juan
Camós-Carreras, Anna
Alba-Arbalat, Salut
Sánchez-Vela, Erika
Llufriu, Sara
Villoslada, Pablo
Sánchez-Dalmau, Bernardo
-
Funding
Funding for this research was provided by:
Instituto de Salud Carlos III (PI20-01236)
Sanofi Genzyme
- License Information
-
More Information
Article History
Received: 25 March 2026
Accepted: 20 July 2026
First Online: 24 July 2026
Declarations
Competing interests: Marc Figueras-Roca, Juan Laraña, Anna Camós-Carreras, Salut Alba-Arbalat, and Erika Sánchez-Vela declare that they have no conflicts of interest. Sara Llufriu has received compensation for consulting services and speaker honoraria from Biogen Idec, Novartis, Johnson & Johnson, Sanofi, Merck, and Bristol-Myers Squibb, and has received research funding from the Instituto de Salud Carlos III and AGAUR. Pablo Villoslada has received consultancy fees and holds equity in Bionure Investment, Accure Therapeutics, Attune Neurosciences, QMENTA, CLight, NeuroPrex, Spiral Therapeutics, and Oculis, none of which are related to the present study. Bernardo Sánchez-Dalmau holds equity in Bionure Investment.
